News Information
Focusing on cutting-edge technology and conveying industry voices
The rapid advancement of AI-driven drug discovery is driving an exponential surge in demand for high-quality molecular interaction data. However, traditional protein‑production methods suffer from low throughput and lengthy assay cycles, making them the most significant bottleneck between wet‑lab experiments and AI models. How can we achieve end-to-end automation, spanning rapid protein preparation to high‑throughput affinity screening? And how can we ensure that wet‑lab assays deliver high‑quality inputs that meet the data‑hungry requirements of AI systems?
2026/06/17
Cell-free expression opens new avenues for studying membrane protein function.
Perotin Bio, leveraging its proprietary cell-free protein expression platform, has established a comprehensive product portfolio ranging from assay kits to end-to-end membrane protein expression services. By incorporating folding‑assisting factors such as nanodiscs and detergents into the expression system, the company effectively enhances the solubility and functional activity of challenging membrane proteins, including multi‑transmembrane receptors, transporters, and ion channels. The company has achieved expression levels and activity at structural‑resolution quality for numerous membrane protein targets, significantly shortening the R&D cycle for research clients—from gene to functional protein.
2026/07/09
Membrane Protein Expression: Overcoming the Bottlenecks through Cell-Free Systems
In protein expression research, membrane proteins have long been notorious for their high failure rates. Despite highly mature optimization strategies—such as expression vector engineering, codon optimization, and host system screening—actual R&D pipelines frequently stall at the same frustrating stage: the inability to obtain stable, high-yield expression products.
2026/07/03
Want to stand out in top-tier biology competitions like iGEM (International Genetically Engineered Machine Competition), but feel held back by the tediousness, time‑consuming nature, and high barriers of traditional cell‑based experiments? The PLD Cell‑Free Protein Expression Kit (PLDK003) is designed for biology education and competitions at every stage—from high school through undergraduate and graduate studies. With its ultra‑simple operation, rapid results, and exceptional versatility, it helps your project get ahead and shine!
2026/06/17
Applications and Future Trends of Cell-Free Protein Expression Technology
Cell-Free Protein Synthesis (CFPS) has grown rapidly in the fields of synthetic and structural biology in recent years. It is steadily evolving from a basic laboratory tool into a vital technology platform for protein engineering and drug discovery. The core of this technology lies in the in vitro reconstitution of transcription and translation systems, enabling the rapid synthesis of target proteins while completely bypassing the complex regulatory networks found inside living cells.
2026/06/10
In the biomedical field, peptides hold a critical position as therapeutics, playing key roles in disease-related metabolic reprogramming and immune regulation. Thanks to their excellent biocompatibility and high specificity, they have become a highly reliable choice for clinical treatments.
2026/05/21
Recently, Dr. Li Xiaobo, Chief Marketing Advisor at Perotin Bio, was invited to visit the Institute of Materia Medica, Chinese Academy of Medical Sciences, where he delivered a specialized academic lecture on cell-free protein expression technology. A large number of researchers from the institute attended and participated in the session.
2026/04/27
The Future of Biopharma is Cell-Free: Partner with PLD Technology to Lead the Frontier
The winds of change are here, and the science-and-tech sector is ripe with opportunity. PLD Technology is a global pioneer in Cell-Free Protein Synthesis (CFPS) technology. By leveraging groundbreaking foundational innovations, we are disrupting industry barriers and capturing market leadership with premium, high-performance products.
2026/04/23
Traditional antibody discovery resembles a marathon: construction, transfection, expression, purification, and screening—processes that can span weeks or even months, with limited throughput and low success rates for difficult-to-express antibodies or toxic proteins. Moreover, many potentially highly active antibodies are mistakenly classified as “negative” due to insufficient expression levels, resulting in the loss of promising candidates. In contrast, cell-free protein synthesis (CFPS) technology creates an “ultra‑fast pathway” for antibody screening, compressing workflows that traditionally take weeks or months down to just days. Drawing on existing literature, CFPS has demonstrated two key advantages in antibody screening:
2026/04/14
Contact Information
Service Hotline: +86-512-67900128
Customer Service: order@sz-pld.tech
Business Cooperation: bd@sz-pld.tech
Address: Room 302, Building 1, Weili Medical Science and Technology Park, No. 69 Jiepu Road, Suzhou Industrial Park
